TROP2: As a Promising Target in Lung Cancer.

Li X and Chen J. Front. Oncol. 2025;15:1569897.

PL02.11 Normalized Membrane Ratio of TROP2 by Quantitative Continuous Scoring is Predictive of Clinical Outcomes in TROPION-Lung 01.

Garassino, MC et al. J Thorac Oncol. 2024;19:S2–S3.

Datopotamab Deruxtecan in Advanced or Metastatic Non–Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study.

Sands J, et al. J Clin Oncol. 2025;43(10):1254-1265.

Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study.

Ahn MJ, et al. J Clin Oncol. 2025;43(3):260-272.

Sacituzumab Tirumotecan in EGFR-TKI-Resistant, EGFR-Mutated Advanced NSCLC.

Fang W, et al. N Engl J Med. 2026;394(1):13-26.

Targeting TROP2 in Drug-Tolerant Persister Cells Delays EGFR Tyrosine Kinase Inhibitor Resistance in Non-Small-Cell Lung Cancer.

Liao J, et al. Cancer Cell. 2026;44:1-17.

Sacituzumab tirumotecan (sac-TMT) plus pembrolizumab (P) versus pembrolizumab (P) as first-line treatment for PD-L1–positive advanced non-small cell lung cancer (NSCLC): Results from the randomized phase 3 OptiTROP-Lung05 study.

Zhou C, et al. J Clin Oncol. 2026;44(suppl 16; abstr 8506).

Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study.

Paz-Ares LG, et al. J Clin Oncol. 2024;42(24):2860-2872.

First-Line Sacituzumab Govitecan Plus Pembrolizumab in Metastatic NSCLC: PD-L1 TPS Less Than 50% and More Than or Equal to 50% Cohorts of the EVOKE-02 Study.

Reck M, et al. J Thorac Oncol. 2026;21(3):103509.

Treatment-Related Adverse Events of Antibody-Drug Conjugate Monotherapy in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.

Li Y, et al. Thorac Cancer. 2025;16(22):e70178.